Abstract
The classification of dopamine receptors proposed more than two decades ago remains valid today. Based on biochemical and pharmaceutical properties two main classes of dopamine receptors can be distuinguished: D1-like (D1, D5) and D2-like (D2, D3, and D4) dopamine receptors. Dopamine receptors belong to the class of G protein-coupled receptors and signal to a wide range of membrane bound and intracellular effectors such as ion channels, secondary messenger systems and enzymes. Although the pharmacological properties of ligands for D1-like and D2-like dopamine receptors are quite different, the number of selective ligands for each of the five receptors subtypes is rather small. Many drugs used to treat neurological and neuropsychiatric disorders like Parkinsons disease, restless leg syndrome and schizophrenia have affinities for dopamine receptors. Such medications are not without limitations so the development of novel (selective or aselective) dopamine receptor ligands is of the utmost importance for improved therapeutic approaches for these diseases. In that respect it is also important to understand how dopamine receptor ligands affect receptor signalling processes such as desensitization, receptor heterodimerization and agonist-receptor trafficking, issues which will be discussed in the present review. Furthermore, attention is paid to interactions of dopamine receptors with serotonin receptors since many drugs used to treat above mentioned disorders of the brain also posses affinities for serotonin receptors. Because of the enormity of this area we have tried to focus more specifically on interactions within the prefrontal cortex where it appears that the serotonergic modulation of dopaminergic function might be very relevant to schizophrenia.
Keywords: prefrontal cortex, restless legs syndrome, schizophrenia, dopaminergic drugs, neurological and neuropsychiatric disorders, receptor classification, signal transduction pathway, Drug efficacy
CNS & Neurological Disorders - Drug Targets
Title: Dopamine Receptor Pharmacology: Interactions with Serotonin Receptors and Significance for the Aetiology and Treatment of Schizophrenia
Volume: 5 Issue: 1
Author(s): J. C. Glennon, W. J. Wadman, A. C. McCreary and T. R. Werkman
Affiliation:
Keywords: prefrontal cortex, restless legs syndrome, schizophrenia, dopaminergic drugs, neurological and neuropsychiatric disorders, receptor classification, signal transduction pathway, Drug efficacy
Abstract: The classification of dopamine receptors proposed more than two decades ago remains valid today. Based on biochemical and pharmaceutical properties two main classes of dopamine receptors can be distuinguished: D1-like (D1, D5) and D2-like (D2, D3, and D4) dopamine receptors. Dopamine receptors belong to the class of G protein-coupled receptors and signal to a wide range of membrane bound and intracellular effectors such as ion channels, secondary messenger systems and enzymes. Although the pharmacological properties of ligands for D1-like and D2-like dopamine receptors are quite different, the number of selective ligands for each of the five receptors subtypes is rather small. Many drugs used to treat neurological and neuropsychiatric disorders like Parkinsons disease, restless leg syndrome and schizophrenia have affinities for dopamine receptors. Such medications are not without limitations so the development of novel (selective or aselective) dopamine receptor ligands is of the utmost importance for improved therapeutic approaches for these diseases. In that respect it is also important to understand how dopamine receptor ligands affect receptor signalling processes such as desensitization, receptor heterodimerization and agonist-receptor trafficking, issues which will be discussed in the present review. Furthermore, attention is paid to interactions of dopamine receptors with serotonin receptors since many drugs used to treat above mentioned disorders of the brain also posses affinities for serotonin receptors. Because of the enormity of this area we have tried to focus more specifically on interactions within the prefrontal cortex where it appears that the serotonergic modulation of dopaminergic function might be very relevant to schizophrenia.
Export Options
About this article
Cite this article as:
Glennon C. J., Wadman J. W., McCreary C. A. and Werkman R. T., Dopamine Receptor Pharmacology: Interactions with Serotonin Receptors and Significance for the Aetiology and Treatment of Schizophrenia, CNS & Neurological Disorders - Drug Targets 2006; 5 (1) . https://dx.doi.org/10.2174/187152706784111614
DOI https://dx.doi.org/10.2174/187152706784111614 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Redox Processes in Neurodegenerative Disease Involving Reactive Oxygen Species
Current Neuropharmacology Neurological Soft Signs in Patients with Psychosis and Cannabis Abuse: A Systematic Review and Meta-Analysis of Paradox
Current Pharmaceutical Design L-DOPA and Serotonergic Neurons: Functional Implication and Therapeutic Perspectives in Parkinson's Disease
Central Nervous System Agents in Medicinal Chemistry Molecular Methods for Individualization of Psychotropic Drug Treatment
Current Pharmacogenomics Current Progresses on Nanodelivery Systems for the Treatment of Neuropsychiatric Diseases: Alzheimer’s and Schizophrenia
Current Pharmaceutical Design Asthma in Childhood – Making the Diagnosis
Current Pediatric Reviews Neurobiological Basis of Dyskinetic Effects Induced by Antipsychotics: the Contribution of Animal Models
Current Medicinal Chemistry Clinical Potential of Yi-Gan San (Yokukansan) for the Treatment of Psychiatric Disorders
Current Psychiatry Reviews Adenosine A<sub>2A</sub> Receptor Antagonists as Positron Emission Tomography (PET) Tracers
Current Medicinal Chemistry Colchicine Protects Dopaminergic Neurons in a Rat Model of Parkinson's Disease
CNS & Neurological Disorders - Drug Targets Neuroimaging Studies of Substance Abuse in Schizophrenia
Current Psychiatry Reviews Tau, Amyloid Beta and Deep Brain Stimulation: Aiming to Restore Cognitive Deficit in Alzheimer's Disease
Current Alzheimer Research The Changing Landscape of Voltage-Gated Calcium Channels in Neurovascular Disorders and in Neurodegenerative Diseases
Current Neuropharmacology Medical Management of Parkinsons Disease: Focus on Neuroprotection
Current Neuropharmacology Systems Biology and Synthetic Biology: Understanding Biological Complexity on the Critical Path to Personalized Medicine
Current Pharmacogenomics and Personalized Medicine The Prevention and Treatment of Delirium in Elderly Patients Following Hip Fracture Surgery
Recent Patents on CNS Drug Discovery (Discontinued) Echocardiographic Hemodynamic Monitoring in the Critically Ill Patient
Current Cardiology Reviews Artificial Neural Network (ANN) Based Modelling for D1 Like and D2 Like Dopamine Receptor Affinity and Selectivity
Medicinal Chemistry Regulation of Dopamine Signaling in the Striatum by Phosphodiesterase Inhibitors: Novel Therapeutics to Treat Neurological and Psychiatric Disorders
Central Nervous System Agents in Medicinal Chemistry Proceedings of the Regional Conference of the International Society for Adolescent Psychiatry and Psychology (ISAPP), a Joint Conference with 18<sup>th</sup> National Symposium of Adolescent Mental Health, Ankara, Turkey, November 21-24, 2013<sup>1</sup>
Adolescent Psychiatry